Physician profile
Wayne A Emineth
NPI 1306804018
$21,717.79
in general payments reported to CMS, 2019-2025
29 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,851 · 2022: $1,221 · 2023: $1,871 · 2024: $2,960 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $7,975 · Food and Beverage: $7,966 · Travel and Lodging: $1,322 · Consulting Fee: $1,140 · Education: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $7,975.00 |
| Food and Beverage | $7,966.43 |
| Travel and Lodging | $1,321.95 |
| Consulting Fee | $1,140.00 |
| Education | $242.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $10,062.95 | 2025 | Vtama |
| Ucb, INC. | $1,858.40 | 2021-2025 | Bimzelx |
| Abbvie INC. | $1,849.36 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,170.81 | 2021-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $882.88 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $632.72 | 2021-2025 | Tremfya, Stelara, Simponi |
| Dermavant Sciences, INC. | $619.05 | 2023-2024 | Vtama |
| Leo Pharma INC. | $600.06 | 2021-2025 | Adbry, Anzupgo |
| Pfizer INC. | $569.69 | 2021-2025 | |
| Genzyme Corporation | $486.12 | 2021-2025 | |
| Incyte Corporation | $468.76 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $358.50 | 2021-2025 | Winlevi, Ilumya |
| Galderma Laboratories, L.P. | $346.97 | 2021-2025 | Nemluvio, Aklief |
| Amgen INC. | $328.35 | 2021-2025 | Otezla, Enbrel |
| Lilly USA, LLC | $273.20 | 2021-2025 | Ebglyss, Taltz, Olumiant |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $211.79 | 2023-2025 | |
| Almirall LLC | $202.77 | 2022-2025 | Seysara |
| Arcutis Biotherapeutics, INC. | $187.42 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $131.21 | 2021-2024 | Jublia, Siliq, Targretin |
| Sanofi-Aventis U.S. LLC | $111.19 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.44 | 2023-2025 | Spevigo |
| Mayne Pharma Commercial LLC | $66.88 | 2023-2024 | |
| Verrica Pharmaceuticals INC. | $62.78 | 2024-2025 | Ycanth |
| Epi Health, LLC | $52.86 | 2021-2022 | |
| Journey Medical Corporation | $26.48 | 2025 | |
| Novo Nordisk INC | $21.94 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.82 | 2021 | |
| Bard Peripheral Vascular, INC. | $18.09 | 2024 | Venclose Maven Catheter |
| Kyowa Kirin, INC. | $15.30 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Emineth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.